LB201 / Centessa, Eli Lilly - LARVOL DELTA

Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022 (GlobeNewswire) - "PD-L1xCD3 LockBody (Undisclosed)- The Company expects to name a product candidate and share preclinical data this year."

Preclinical • Oncology • Solid Tumor

Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update (GlobeNewswire) - "Upcoming Program Milestones - LB101 and LB201 in Solid Tumors: LB101, a PD-L1xCD47 LockBody®, is designed to selectively drive potent CD47 effector function activity while avoiding systemic toxicity. We anticipate sharing foundational preclinical data at ASCO 2022, with an IND for LB101 planned for late 2022. LB201, a PD-L1xCD3 LockBody®, is designed to selectively drive potent CD3 effector function activity while avoiding systemic toxicity. IND for LB201 is planned for 2023."

IND • Preclinical • Oncology • Solid Tumor